Calliditas
1991
FOUNDED
PUBLIC
STATUS
11-20
EMPLOYEES
CALTX
STOCK SYMBOL
1
INVESTMENTS
$8.93
SHARE PRICE
(As of Friday Closing)
Description
Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.
Website
Formerly Known As
Pharmalink
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Pharmaceuticals
Stock Exchange
STO
Primary Office
- Wallingatan 26B
- 111 24 Stockholm
- Sweden
+46 08-411 00 00
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Calliditas’s full profile, request a free trial.
Calliditas Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $4.22 - $9.40 | $346M | $8.78 | -$0.16 | 36.1K | 38.7M |
Calliditas Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 150,286 | 95,210 | ||
| Revenue | 14,840 | 0 | 0 | 0 |
| EBITDA | (5,827) | (15,170) | (9,887) | (6,511) |
| Net Income | (5,770) | (15,176) | (10,155) | (6,642) |
| Total Assets | 85,876 | 72,136 | 7,608 | 2,997 |
| Total Debt | 0 | 0 | 57 | 3,294 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Calliditas Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Calliditas‘s full profile, request access.
Request full access to PitchBookCalliditas Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 18-Mar-2015 | 000000000000000000 | Drug Discovery |
Calliditas Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Calliditas‘s full profile, request access.
Request full access to PitchBookCalliditas Executive Team (15)
3 Former Executives
You’re viewing 5 of 15 executives. Get the full list »Calliditas Board Members (9)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Ann-Tove Kongsnes | Investinor | Board Member | 000 0000 | |
| Bengt Julander | Self | Co-Founder & Board Member | 000 0000 | |
| Diane Parks | Calliditas | Board Member | 000 0000 | |
| Elmar Schnee | Self | Chairman | 000 0000 | |
| Hilde Furberg | Self | Board Member | 000 0000 |
2 Former Board Members
You’re viewing 5 of 9 board members. Get the full list »